White House denies Trump accessed unauthorized weight-loss drug

The White House has strongly denied allegations that President Donald Trump received access to an unauthorized weight-loss medication. The claim originated from STAT, a specialized health news magazine, which reported that pharmaceutical company Eli Lilly had provided an experimental drug to a patient matching the president's profile through a "compassionate use" program.

This program allows patients with life-threatening conditions to access experimental treatments. STAT indicated it had sought comment from the White House, the Department of Health and Human Services (HHS), and the Food and Drug Administration (FDA) but received no direct responses. White House Deputy Press Secretary Kush Desai dismissed the report, labeling the author, Lizzy Lawrence, as a "gossip writer" and casting doubt on the article's veracity.

“

The White House denied the fact and questioned the credibility of STAT, a magazine specialized in health reporting that published an article claiming the pharmaceutical company Eli Lily provided an extraordinary medication to a patient with the president's characteristics.

President Trump's health has been a subject of public interest, particularly following a noticeable weight loss. A medical report released by the White House in May stated that Trump is in "excellent health." His physician attributed the weight loss to dietary changes and increased physical activity, affirming his fitness for the presidency.

STAT's report suggested that Eli Lilly and the FDA facilitated access to the medication for an individual under the FDA's "compassionate use" provision. However, the White House's firm denial and Desai's sharp criticism of the reporting cast significant doubt on the accuracy of the magazine's claims.

“

gossip writer